Pub Date : 2024-10-23eCollection Date: 2024-01-01DOI: 10.3389/fnume.2024.1477467
Amaila Ramzan, Amarjot Chander, Thomas Westwood, Mark Elias, Prakash Manoharan
Hibernomas are rare brown fat tumors that garnered attention in the literature with the increasing use of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ([18F] FDG PET/CT) for the staging workup and follow-up of solid malignancies. Despite being benign tumors, they exhibit high metabolic activity due to their thermogenic nature, leading to significant radiotracer uptake on functional imaging. This can pose a challenge in differentiating them from the malignant lesions, especially the fat-containing malignancies such as liposarcoma. Hibernomas are typically found in the thigh, shoulder, back, and neck. Here, we present a unique case of Hibernoma in a patient undergoing PET/CT for melanoma follow-up in an unusual perihepatic location. To the best of the authors' knowledge, this represents the first reported case of a perihepatic hibernoma in the literature. The report also offers a literature review on hibernomas, including the influence of ambient temperature on their metabolism, diagnostic challenges, management strategies, and reports of hibernomas detected on functional imaging with a range of radiotracers. These observations could serve as a valuable clue in identifying hibernomas, potentially aiding in avoiding unnecessary biopsies or resections.
{"title":"Case Report: All that glitters is not cancer; perihepatic hibernoma with fluctuating FDG uptake on PET/CT.","authors":"Amaila Ramzan, Amarjot Chander, Thomas Westwood, Mark Elias, Prakash Manoharan","doi":"10.3389/fnume.2024.1477467","DOIUrl":"10.3389/fnume.2024.1477467","url":null,"abstract":"<p><p>Hibernomas are rare brown fat tumors that garnered attention in the literature with the increasing use of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ([<sup>18</sup>F] FDG PET/CT) for the staging workup and follow-up of solid malignancies. Despite being benign tumors, they exhibit high metabolic activity due to their thermogenic nature, leading to significant radiotracer uptake on functional imaging. This can pose a challenge in differentiating them from the malignant lesions, especially the fat-containing malignancies such as liposarcoma. Hibernomas are typically found in the thigh, shoulder, back, and neck. Here, we present a unique case of Hibernoma in a patient undergoing PET/CT for melanoma follow-up in an unusual perihepatic location. To the best of the authors' knowledge, this represents the first reported case of a perihepatic hibernoma in the literature. The report also offers a literature review on hibernomas, including the influence of ambient temperature on their metabolism, diagnostic challenges, management strategies, and reports of hibernomas detected on functional imaging with a range of radiotracers. These observations could serve as a valuable clue in identifying hibernomas, potentially aiding in avoiding unnecessary biopsies or resections.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ionising radiation (IR) is a form of energy that travels as electromagnetic waves or particles. While it is vital in medical and occupational health settings, IR can also damage DNA, leading to mutations, chromosomal aberrations, and transcriptional changes that disrupt the functions of certain cell regulators, genes, and transcription factors. These disruptions can alter functions critical for cancer development, progression, and treatment response. Additionally, IR can affect various cellular proteins and their regulators within different cell signalling pathways, resulting in physiological changes that may promote cancer development, progression, and resistance to treatment. Understanding these impacts is crucial for developing strategies to mitigate the harmful effects of IR exposure and improve cancer treatment outcomes. This review focuses on specific genes and protein biomarkers regulated in response to chronic IR exposure, and how their regulation impacts disease onset, progression, and treatment response.
{"title":"Ionising radiation exposure-induced regulation of selected biomarkers and their impact in cancer and treatment.","authors":"Yonwaba Mzizi, Saidon Mbambara, Boitumelo Moetlhoa, Johncy Mahapane, Sipho Mdanda, Mike Sathekge, Mankgopo Kgatle","doi":"10.3389/fnume.2024.1469897","DOIUrl":"10.3389/fnume.2024.1469897","url":null,"abstract":"<p><p>Ionising radiation (IR) is a form of energy that travels as electromagnetic waves or particles. While it is vital in medical and occupational health settings, IR can also damage DNA, leading to mutations, chromosomal aberrations, and transcriptional changes that disrupt the functions of certain cell regulators, genes, and transcription factors. These disruptions can alter functions critical for cancer development, progression, and treatment response. Additionally, IR can affect various cellular proteins and their regulators within different cell signalling pathways, resulting in physiological changes that may promote cancer development, progression, and resistance to treatment. Understanding these impacts is crucial for developing strategies to mitigate the harmful effects of IR exposure and improve cancer treatment outcomes. This review focuses on specific genes and protein biomarkers regulated in response to chronic IR exposure, and how their regulation impacts disease onset, progression, and treatment response.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-11eCollection Date: 2024-01-01DOI: 10.3389/fnume.2024.1472500
Anzhelika N Moiseeva, Chiara Favaretto, Zeynep Talip, Pascal V Grundler, Nicholas P van der Meulen
The interest in terbium radionuclides, which can be used in nuclear medicine, has increased tremendously over the last decade. Several research studies have shown the potential of four terbium radionuclides 149,152,155,161Tb both for cancer diagnosis as well as therapy. The comparison of 161Tb and 177Lu showed 161Tb as the preferred candidate not only for standard radiotherapy, but also for the treatment of minimal residual disease. Nevertheless, among the terbium sisters, currently, only 161Tb has an established production protocol where its no-carrier-added form is obtained via neutron irradiation of enriched 160Gd targets. The other terbium radioisotopes face challenges related to production capacity and production yield, which currently restricts their use in nuclear medicine. The purpose of this review is to report on recent research on the production and separation of terbium sisters and to assess the prospects for upscaling their production for nuclear medicine applications.
{"title":"Terbium sisters: current development status and upscaling opportunities.","authors":"Anzhelika N Moiseeva, Chiara Favaretto, Zeynep Talip, Pascal V Grundler, Nicholas P van der Meulen","doi":"10.3389/fnume.2024.1472500","DOIUrl":"10.3389/fnume.2024.1472500","url":null,"abstract":"<p><p>The interest in terbium radionuclides, which can be used in nuclear medicine, has increased tremendously over the last decade. Several research studies have shown the potential of four terbium radionuclides <sup>149,152,155,161</sup>Tb both for cancer diagnosis as well as therapy. The comparison of <sup>161</sup>Tb and <sup>177</sup>Lu showed <sup>161</sup>Tb as the preferred candidate not only for standard radiotherapy, but also for the treatment of minimal residual disease. Nevertheless, among the terbium sisters, currently, only <sup>161</sup>Tb has an established production protocol where its no-carrier-added form is obtained via neutron irradiation of enriched <sup>160</sup>Gd targets. The other terbium radioisotopes face challenges related to production capacity and production yield, which currently restricts their use in nuclear medicine. The purpose of this review is to report on recent research on the production and separation of terbium sisters and to assess the prospects for upscaling their production for nuclear medicine applications.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-11eCollection Date: 2024-01-01DOI: 10.3389/fnume.2024.1481343
Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Lisa McDougall, Anass Johayem, Milen Blagoev, Francesco De Rose, Leila Jaafar-Thiel, Melpomeni Fani
<p><strong>Background: </strong>Gallium-68 positron emission tomography (<sup>68</sup>Ga-PET) with the two registered somatostatin analogs, [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotide ([<sup>68</sup>Ga]Ga-DOTA-TOC) and [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotate ([<sup>68</sup>Ga]Ga-DOTA-TATE), where DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is routinely used for imaging of somatostatin receptor (SST)-expressing tumors. We investigated copper-61 (<sup>61</sup>Cu) as an alternative radiometal for PET imaging of SST-expressing tumors. Compared to gallium-68, copper-61 (t<sub>1/2</sub> = 3.33 h, E <i><sub>β</sub></i> <sup>+</sup> <sub>max</sub> = 1.22 MeV) can be produced on a large scale, enables late time point imaging, and has the therapeutic twin copper-67. Herein, DOTA-TOC and 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-TOC were labeled with copper-61 and compared with the clinically used [<sup>68</sup>Ga]Ga-DOTA-TOC.</p><p><strong>Methods: </strong>[<sup>61</sup>Cu]CuCl<sub>2</sub> was produced from an irradiated natural nickel target. DOTA-TOC and NODAGA-TOC were labeled with [<sup>61</sup>Cu]CuCl<sub>2</sub> in ammonium acetate buffer so to achieve a reaction pH of 5-6 and a temperature of 95°C for DOTA-TOC or room temperature for NODAGA-TOC. The radioligands were evaluated head-to-head <i>in vitro</i> using human embryonic kidney (HEK)-SST<sub>2</sub> cells (affinity, binding sites, cellular uptake, and efflux) and <i>in vivo</i> using HEK-SST<sub>2</sub> xenografts [PET/computed tomography (CT) imaging, biodistribution, and pharmacokinetics] and compared with [<sup>68</sup>Ga]Ga-DOTA-TOC, which was prepared using a standard procedure. Dosimetry estimates were made for [<sup>61</sup>Cu]Cu-NODAGA-TOC.</p><p><strong>Results: </strong>[<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC were prepared at an apparent molar activity of 25 MBq/nmol with radiochemical purities of ≥96% and ≥98%, respectively. <i>In vitro</i>, both presented a sub-nanomolar affinity for SST<sub>2</sub> (IC<sub>50</sub> = 0.23 and 0.34 nM, respectively). They were almost entirely internalized upon binding to SST<sub>2</sub>-expressing cells and had similar efflux rates at 37°C. <i>In vivo</i>, [<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC showed the same accumulation in SST<sub>2</sub>-expressing tumors. However, PET/CT images and biodistribution analyses clearly showed an unfavorable biodistribution for [<sup>61</sup>Cu]Cu-DOTA-TOC, characterized by accumulation in the liver and the abdomen. [<sup>61</sup>Cu]Cu-NODAGA-TOC displayed favorable biodistribution, comparable with [<sup>68</sup>Ga]Ga-DOTA-TOC at 1 h post-injection (p.i.). Notwithstanding, [<sup>61</sup>Cu]Cu-NODAGA-TOC showed advantages at 4 h p.i., due to the tumor retention and improved tumor-to-non-tumor ratios. The effective dose (2.41 × 10<sup>-3</sup> mSv/MBq) of [<sup>61</sup>Cu]Cu-NODAGA-TOC, but also the dose t
{"title":"Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.","authors":"Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Lisa McDougall, Anass Johayem, Milen Blagoev, Francesco De Rose, Leila Jaafar-Thiel, Melpomeni Fani","doi":"10.3389/fnume.2024.1481343","DOIUrl":"10.3389/fnume.2024.1481343","url":null,"abstract":"<p><strong>Background: </strong>Gallium-68 positron emission tomography (<sup>68</sup>Ga-PET) with the two registered somatostatin analogs, [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotide ([<sup>68</sup>Ga]Ga-DOTA-TOC) and [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotate ([<sup>68</sup>Ga]Ga-DOTA-TATE), where DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is routinely used for imaging of somatostatin receptor (SST)-expressing tumors. We investigated copper-61 (<sup>61</sup>Cu) as an alternative radiometal for PET imaging of SST-expressing tumors. Compared to gallium-68, copper-61 (t<sub>1/2</sub> = 3.33 h, E <i><sub>β</sub></i> <sup>+</sup> <sub>max</sub> = 1.22 MeV) can be produced on a large scale, enables late time point imaging, and has the therapeutic twin copper-67. Herein, DOTA-TOC and 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-TOC were labeled with copper-61 and compared with the clinically used [<sup>68</sup>Ga]Ga-DOTA-TOC.</p><p><strong>Methods: </strong>[<sup>61</sup>Cu]CuCl<sub>2</sub> was produced from an irradiated natural nickel target. DOTA-TOC and NODAGA-TOC were labeled with [<sup>61</sup>Cu]CuCl<sub>2</sub> in ammonium acetate buffer so to achieve a reaction pH of 5-6 and a temperature of 95°C for DOTA-TOC or room temperature for NODAGA-TOC. The radioligands were evaluated head-to-head <i>in vitro</i> using human embryonic kidney (HEK)-SST<sub>2</sub> cells (affinity, binding sites, cellular uptake, and efflux) and <i>in vivo</i> using HEK-SST<sub>2</sub> xenografts [PET/computed tomography (CT) imaging, biodistribution, and pharmacokinetics] and compared with [<sup>68</sup>Ga]Ga-DOTA-TOC, which was prepared using a standard procedure. Dosimetry estimates were made for [<sup>61</sup>Cu]Cu-NODAGA-TOC.</p><p><strong>Results: </strong>[<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC were prepared at an apparent molar activity of 25 MBq/nmol with radiochemical purities of ≥96% and ≥98%, respectively. <i>In vitro</i>, both presented a sub-nanomolar affinity for SST<sub>2</sub> (IC<sub>50</sub> = 0.23 and 0.34 nM, respectively). They were almost entirely internalized upon binding to SST<sub>2</sub>-expressing cells and had similar efflux rates at 37°C. <i>In vivo</i>, [<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC showed the same accumulation in SST<sub>2</sub>-expressing tumors. However, PET/CT images and biodistribution analyses clearly showed an unfavorable biodistribution for [<sup>61</sup>Cu]Cu-DOTA-TOC, characterized by accumulation in the liver and the abdomen. [<sup>61</sup>Cu]Cu-NODAGA-TOC displayed favorable biodistribution, comparable with [<sup>68</sup>Ga]Ga-DOTA-TOC at 1 h post-injection (p.i.). Notwithstanding, [<sup>61</sup>Cu]Cu-NODAGA-TOC showed advantages at 4 h p.i., due to the tumor retention and improved tumor-to-non-tumor ratios. The effective dose (2.41 × 10<sup>-3</sup> mSv/MBq) of [<sup>61</sup>Cu]Cu-NODAGA-TOC, but also the dose t","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05eCollection Date: 2024-01-01DOI: 10.3389/fnume.2024.1380518
Muyang Zhang, Robert G Aykroyd, Charalampos Tsoumpas
The diagnosis of medical conditions and subsequent treatment often involves radionuclide imaging techniques. To refine localisation accuracy and improve diagnostic confidence, compared with the use of a single scanning technique, a combination of two (or more) techniques can be used but with a higher risk of misalignment. For this to be reliable and accurate, recorded data undergo processing to suppress noise and enhance resolution. A step in image processing techniques for such inverse problems is the inclusion of smoothing. Standard approaches, however, are usually limited to applying identical models globally. In this study, we propose a novel Laplace and Gaussian mixture prior distribution that incorporates different smoothing strategies with the automatic model-based estimation of mixture component weightings creating a locally adaptive model. A fully Bayesian approach is presented using multi-level hierarchical modelling and Markov chain Monte Carlo (MCMC) estimation methods to sample from the posterior distribution and hence perform estimation. The proposed methods are assessed using simulated camera images and demonstrate greater noise reduction than existing methods but without compromising resolution. As well as image estimates, the MCMC methods also provide posterior variance estimates and hence uncertainty quantification takes into consideration any potential sources of variability. The use of mixture prior models, part Laplace random field and part Gaussian random field, within a Bayesian modelling approach is not limited to medical imaging applications but provides a more general framework for analysing other spatial inverse problems. Locally adaptive prior distributions provide a more realistic model, which leads to robust results and hence more reliable decision-making, especially in nuclear medicine. They can become a standard part of the toolkit of everyone working in image processing applications.
{"title":"Mixture prior distributions and Bayesian models for robust radionuclide image processing.","authors":"Muyang Zhang, Robert G Aykroyd, Charalampos Tsoumpas","doi":"10.3389/fnume.2024.1380518","DOIUrl":"10.3389/fnume.2024.1380518","url":null,"abstract":"<p><p>The diagnosis of medical conditions and subsequent treatment often involves radionuclide imaging techniques. To refine localisation accuracy and improve diagnostic confidence, compared with the use of a single scanning technique, a combination of two (or more) techniques can be used but with a higher risk of misalignment. For this to be reliable and accurate, recorded data undergo processing to suppress noise and enhance resolution. A step in image processing techniques for such inverse problems is the inclusion of smoothing. Standard approaches, however, are usually limited to applying identical models globally. In this study, we propose a novel Laplace and Gaussian mixture prior distribution that incorporates different smoothing strategies with the automatic model-based estimation of mixture component weightings creating a locally adaptive model. A fully Bayesian approach is presented using multi-level hierarchical modelling and Markov chain Monte Carlo (MCMC) estimation methods to sample from the posterior distribution and hence perform estimation. The proposed methods are assessed using simulated <math><mi>γ</mi> <msup><mtext>-eye</mtext> <mrow><mtext>TM</mtext></mrow> </msup> </math> camera images and demonstrate greater noise reduction than existing methods but without compromising resolution. As well as image estimates, the MCMC methods also provide posterior variance estimates and hence uncertainty quantification takes into consideration any potential sources of variability. The use of mixture prior models, part Laplace random field and part Gaussian random field, within a Bayesian modelling approach is not limited to medical imaging applications but provides a more general framework for analysing other spatial inverse problems. Locally adaptive prior distributions provide a more realistic model, which leads to robust results and hence more reliable decision-making, especially in nuclear medicine. They can become a standard part of the toolkit of everyone working in image processing applications.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-14eCollection Date: 2024-01-01DOI: 10.3389/fnume.2024.1446780
Jiequn Weng, Jie Lin, Chong Sun
Peripheral neuropathy is a prevalent complication in plasma cell disorders, posing significant diagnostic and therapeutic challenges. This study presents three cases initially diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite initial symptom regression post-immunomodulatory treatment, the patients exhibited progressive neurological deficits. Advanced laboratory evaluation confirmed monoclonal protein presence, yet traditional diagnostic methods, including bone marrow biopsy and flow cytometry, yielded normal results. Utilizing 18F-FDG PET/CT, we identified multiple hypermetabolic vertebral lesions, which upon biopsy, confirmed the diagnosis of plasmacytoma. Our findings underscore the utility of PET/CT as a reliable diagnostic tool for monoclonal gammopathy associated neuropathy, advocating for its consideration in cases with equivocal diagnosis. When the diagnosis is in doubt, biopsy of a lesion may facilitate early and accurate diagnosis, potentially influencing treatment strategies and patient outcomes.
{"title":"Case Report: Application of <sup>18</sup>F-FDG PET/CT in identifying plasmacytoma in monoclonal gammopathy associated peripheral neuropathy.","authors":"Jiequn Weng, Jie Lin, Chong Sun","doi":"10.3389/fnume.2024.1446780","DOIUrl":"10.3389/fnume.2024.1446780","url":null,"abstract":"<p><p>Peripheral neuropathy is a prevalent complication in plasma cell disorders, posing significant diagnostic and therapeutic challenges. This study presents three cases initially diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite initial symptom regression post-immunomodulatory treatment, the patients exhibited progressive neurological deficits. Advanced laboratory evaluation confirmed monoclonal protein presence, yet traditional diagnostic methods, including bone marrow biopsy and flow cytometry, yielded normal results. Utilizing <sup>18</sup>F-FDG PET/CT, we identified multiple hypermetabolic vertebral lesions, which upon biopsy, confirmed the diagnosis of plasmacytoma. Our findings underscore the utility of PET/CT as a reliable diagnostic tool for monoclonal gammopathy associated neuropathy, advocating for its consideration in cases with equivocal diagnosis. When the diagnosis is in doubt, biopsy of a lesion may facilitate early and accurate diagnosis, potentially influencing treatment strategies and patient outcomes.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-02eCollection Date: 2024-01-01DOI: 10.3389/fnume.2024.1451848
Hicham Moukaddam, Ghida El Saheb, Nadine Omran, Nour El Ghawi, Alain Abi Ghanem, Mohamad Haidar
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an imaging technique that has demonstrated high sensitivity and specificity in detecting prostate cancer and its metastasis, especially in the bones. This case describes a 60-year-old man who presented for increased prostate-specific antigen (PSA) level and underwent [68Ga]gallium-PSMA-11 PET/CT imaging for better disease assessment. 68Ga-PSMA-11 PET/CT revealed numerous radiotracer-positive lesions in both prostate lobes with associated sclerotic lesions on L4 and L5, but only L5 showed increased radiotracer avidity raising the possibility of metastasis. Magnetic Resonance Imaging (MRI) raises the possibility of aggressive MODIC type 1 lesion vs. infectious/inflammatory process. A biopsy of the radiotracer avid area was performed and showed no evidence of metastasis. The final diagnosis was aggressive MODIC type 1, in keeping with the false positive result of 68Ga-PSMA-11 PET/CT. This example demonstrates the possible limitations of 68Ga-PSMA-11 PET/CT, particularly in detecting bone metastases, and emphasizes the need for cautious interpretation and additional study to improve its diagnostic accuracy. Understanding and resolving these limitations is critical for increasing the accuracy of PSMA PET/CT in prostate cancer management.
{"title":"Case report: positive pitfalls of PSMA PET/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1.","authors":"Hicham Moukaddam, Ghida El Saheb, Nadine Omran, Nour El Ghawi, Alain Abi Ghanem, Mohamad Haidar","doi":"10.3389/fnume.2024.1451848","DOIUrl":"10.3389/fnume.2024.1451848","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an imaging technique that has demonstrated high sensitivity and specificity in detecting prostate cancer and its metastasis, especially in the bones. This case describes a 60-year-old man who presented for increased prostate-specific antigen (PSA) level and underwent [<sup>68</sup>Ga]gallium-PSMA-11 PET/CT imaging for better disease assessment. <sup>68</sup>Ga-PSMA-11 PET/CT revealed numerous radiotracer-positive lesions in both prostate lobes with associated sclerotic lesions on L4 and L5, but only L5 showed increased radiotracer avidity raising the possibility of metastasis. Magnetic Resonance Imaging (MRI) raises the possibility of aggressive MODIC type 1 lesion vs. infectious/inflammatory process. A biopsy of the radiotracer avid area was performed and showed no evidence of metastasis. The final diagnosis was aggressive MODIC type 1, in keeping with the false positive result of <sup>68</sup>Ga-PSMA-11 PET/CT. This example demonstrates the possible limitations of <sup>68</sup>Ga-PSMA-11 PET/CT, particularly in detecting bone metastases, and emphasizes the need for cautious interpretation and additional study to improve its diagnostic accuracy. Understanding and resolving these limitations is critical for increasing the accuracy of PSMA PET/CT in prostate cancer management.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-08eCollection Date: 2023-01-01DOI: 10.3389/fnume.2023.1324562
Georg Schramm, Kris Thielemans
In this article, we introduce parallelproj, a novel open-source framework designed for efficient parallel computation of projections in tomography leveraging either multiple CPU cores or GPUs. This framework efficiently implements forward and back projection functions for both sinogram and listmode data, utilizing Joseph's method, which is further extended to encompass time-of-flight (TOF) PET projections. Our evaluation involves a series of tests focusing on PET image reconstruction using data sourced from a state-of-the-art clinical PET/CT system. We thoroughly benchmark the performance of the projectors in non-TOF and TOF, sinogram, and listmode employing multi CPU-cores, hybrid CPU/GPU, and exclusive GPU mode. Moreover, we also investigate the timing of non-TOF sinogram projections calculated in STIR (Software for Tomographic Image Reconstruction) which recently integrated parallelproj as one of its projection backends. Our results indicate that the exclusive GPU mode provides acceleration factors between 25 and 68 relative to the multi-CPU-core mode. Furthermore, we demonstrate that OSEM listmode reconstruction of state-of-the-art real-world PET data sets is achievable within a few seconds using a single consumer GPU.
在本文中,我们将介绍一个新颖的开源框架--parallelproj,该框架旨在利用多个 CPU 内核或 GPU 高效并行计算断层摄影中的投影。该框架利用约瑟夫方法有效地实现了正弦图和列表模式数据的正向和反向投影功能,并进一步扩展到飞行时间(TOF)PET 投影。我们的评估包括一系列测试,重点是使用来自最先进的临床 PET/CT 系统的数据重建 PET 图像。我们采用多 CPU 核、CPU/GPU 混合模式和独占 GPU 模式,对投影仪在非 TOF 和 TOF、正弦图和列表模式下的性能进行了全面的基准测试。此外,我们还研究了在 STIR(断层图像重建软件)中计算的非 TOF 正弦曲线投影的时序,该软件最近集成了 parallelproj 作为其投影后端之一。我们的研究结果表明,相对于多 CPU 内核模式,独占 GPU 模式可提供 25 到 68 倍的加速度。此外,我们还证明了使用单个消费级 GPU 在几秒钟内就能完成最先进的真实 PET 数据集的 OSEM 列表模式重建。
{"title":"PARALLELPROJ-an open-source framework for fast calculation of projections in tomography.","authors":"Georg Schramm, Kris Thielemans","doi":"10.3389/fnume.2023.1324562","DOIUrl":"10.3389/fnume.2023.1324562","url":null,"abstract":"<p><p>In this article, we introduce parallelproj, a novel open-source framework designed for efficient parallel computation of projections in tomography leveraging either multiple CPU cores or GPUs. This framework efficiently implements forward and back projection functions for both sinogram and listmode data, utilizing Joseph's method, which is further extended to encompass time-of-flight (TOF) PET projections. Our evaluation involves a series of tests focusing on PET image reconstruction using data sourced from a state-of-the-art clinical PET/CT system. We thoroughly benchmark the performance of the projectors in non-TOF and TOF, sinogram, and listmode employing multi CPU-cores, hybrid CPU/GPU, and exclusive GPU mode. Moreover, we also investigate the timing of non-TOF sinogram projections calculated in STIR (Software for Tomographic Image Reconstruction) which recently integrated parallelproj as one of its projection backends. Our results indicate that the exclusive GPU mode provides acceleration factors between 25 and 68 relative to the multi-CPU-core mode. Furthermore, we demonstrate that OSEM listmode reconstruction of state-of-the-art real-world PET data sets is achievable within a few seconds using a single consumer GPU.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-06eCollection Date: 2023-01-01DOI: 10.3389/fnume.2023.1284558
A Lim, M Andriotty, T Yusufaly, G Agasthya, B Lee, C Wang
Introduction: We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.
Methods: The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a "pre-calculated" data library, constructed using the RTS code TOPAS-nBio, with "time stamps" manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published in vitro experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental in vitro system consisting of neuroendocrine tumor cells uniformly incubated with 177Lu.
Results and discussion: The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective "in silico clonogenic cell survival assay" for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.
简介:我们开发了一种新方法,可大幅加快放射生物学蒙特卡洛辐射轨迹结构(MC-RTS)计算的速度:我们开发了一种新方法,可大大加快逐个细胞的放射生物学蒙特卡洛辐射轨迹结构(MC-RTS)计算速度:该技术基于随机抽样和单粒子轨道(SPT)标准 DNA 损伤(SDD)文件的叠加,这些文件来自使用 RTS 代码 TOPAS-nBio 构建的 "预计算 "数据文件库,并人工添加了 "时间戳 "以纳入剂量率效应。这种带有时间戳的 SDD 文件随后可输入 MEDRAS,这是一种机理动力学模型,可计算各种辐射诱导的生物终点,如 DNA 双链断裂(DSB)、错误修复和染色体畸变以及细胞死亡。作为该方法的基准验证,我们计算了预测的随能量变化的DSB产量和DNA直接损伤与总损伤之比,两者均与已发表的体外实验数据一致。随后,我们应用该方法对神经内分泌肿瘤细胞均匀培养 177Lu 的体外实验系统进行了逐个细胞的超快速模拟:辐照后24小时和48小时的残余DSB结果与已发表的文献值一致。我们的工作证明了经济有效的 "硅学克隆细胞存活测定 "的可行性,可用于放射性药物和新型放射治疗方法的计算设计和开发。
{"title":"A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data.","authors":"A Lim, M Andriotty, T Yusufaly, G Agasthya, B Lee, C Wang","doi":"10.3389/fnume.2023.1284558","DOIUrl":"10.3389/fnume.2023.1284558","url":null,"abstract":"<p><strong>Introduction: </strong>We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.</p><p><strong>Methods: </strong>The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a \"pre-calculated\" data library, constructed using the RTS code TOPAS-nBio, with \"time stamps\" manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published <i>in vitro</i> experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental <i>in vitro</i> system consisting of neuroendocrine tumor cells uniformly incubated with <sup>177</sup>Lu.</p><p><strong>Results and discussion: </strong>The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective \"<i>in silico</i> clonogenic cell survival assay\" for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-27eCollection Date: 2023-01-01DOI: 10.3389/fnume.2023.1319952
Marina Nearchou, Elizabeth Georgiou, Alexis Vrachimis, Konstantinos Ferentinos, Iosif Strouthos
Background: 18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.
Case presentation: A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT). PSMA-PET/CT revealed a histologically confirmed prostatic malignancy in the peripheral left zone. Unexpectedly, additional multiple highly PSMA-expressing intraabdominal formations were discovered. Based on apparent anatomic asplenia and a history of traumatic splenic rapture during childhood, a suspicion of post-traumatic splenosis was raised. For further non-invasive evaluation, a C-99 sulphur colloid scintigraphy with SPECT was conducted, confirming the presence of multiple functional ectopic splenic tissues. This is, to our best of knowledge, the first case utilising 18F-PSMA-1007-PET/CT and 99mTc-sulphur colloid SPECT to detect intraabdominal splenosis, highlighting the high potential of nuclear medicine in such trivial cases.
{"title":"Case Report: Post-traumatic splenosis and potential pitfall for PSMA-PET.","authors":"Marina Nearchou, Elizabeth Georgiou, Alexis Vrachimis, Konstantinos Ferentinos, Iosif Strouthos","doi":"10.3389/fnume.2023.1319952","DOIUrl":"10.3389/fnume.2023.1319952","url":null,"abstract":"<p><strong>Background: </strong>18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.</p><p><strong>Case presentation: </strong>A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT). PSMA-PET/CT revealed a histologically confirmed prostatic malignancy in the peripheral left zone. Unexpectedly, additional multiple highly PSMA-expressing intraabdominal formations were discovered. Based on apparent anatomic asplenia and a history of traumatic splenic rapture during childhood, a suspicion of post-traumatic splenosis was raised. For further non-invasive evaluation, a C-99 sulphur colloid scintigraphy with SPECT was conducted, confirming the presence of multiple functional ectopic splenic tissues. This is, to our best of knowledge, the first case utilising 18F-PSMA-1007-PET/CT and 99mTc-sulphur colloid SPECT to detect intraabdominal splenosis, highlighting the high potential of nuclear medicine in such trivial cases.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}